Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).

Article Details

Citation

Pajeva IK, Wiese M

Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).

J Med Chem. 2002 Dec 19;45(26):5671-86.

PubMed ID
12477351 [ View in PubMed
]
Abstract

A general pharmacophore model of P-glycoprotein (P-gp) drugs is proposed that is based on a highly diverse data set and relates to the verapamil binding site of the protein. It is derived from structurally different drugs using the program GASP. The pharmacophore model consists of two hydrophobic points, three hydrogen bond (HB) acceptor points, and one HB donor point. Pharmacophore patterns of various drugs are obtained, and different binding modes are presumed for some of them. It is concluded that the binding affinity of the drugs depends on the number of the pharmacophore points simultaneously involved in the interaction with P-gp. On the basis of the obtained results, a hypothesis is proposed to explain the broad structural variety of the P-gp substrates and inhibitors: (i) the verapamil binding site of P-gp has several points that can participate in hydrophobic and HB interactions; (ii) different drugs can interact with different receptor points in different binding modes.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AmiodaroneP-glycoprotein 1Ki (nM)3200N/AN/ADetails
ChlorpromazineP-glycoprotein 1Ki (nM)12200N/AN/ADetails
ChlorpromazineP-glycoprotein 1Ki (nM)600N/AN/ADetails
HaloperidolP-glycoprotein 1Ki (nM)200N/AN/ADetails
HaloperidolP-glycoprotein 1IC 50 (nM)5300N/AN/ADetails
KetoconazoleP-glycoprotein 1IC 50 (nM)13000N/AN/ADetails
KetoconazoleP-glycoprotein 1Ki (nM)1200N/AN/ADetails
OmeprazoleP-glycoprotein 1IC 50 (nM)97200N/AN/ADetails
OmeprazoleP-glycoprotein 1IC 50 (nM)91200N/AN/ADetails
OmeprazoleP-glycoprotein 1IC 50 (nM)89000N/AN/ADetails
PropafenoneP-glycoprotein 1Ki (nM)4200N/AN/ADetails
PropranololP-glycoprotein 1Ki (nM)170000N/AN/ADetails
PropranololP-glycoprotein 1IC 50 (nM)573000N/AN/ADetails
PropranololP-glycoprotein 1IC 50 (nM)574000N/AN/ADetails
PropranololP-glycoprotein 1Ki (nM)48000N/AN/ADetails
QuinidineP-glycoprotein 1Ki (nM)2600N/AN/ADetails
QuinidineP-glycoprotein 1Ki (nM)5000N/AN/ADetails
QuinidineP-glycoprotein 1IC 50 (nM)340000N/AN/ADetails
QuinineP-glycoprotein 1Ki (nM)12000N/AN/ADetails
QuinineP-glycoprotein 1IC 50 (nM)430000N/AN/ADetails
ReserpineP-glycoprotein 1Ki (nM)100N/AN/ADetails
TamoxifenP-glycoprotein 1Ki (nM)100N/AN/ADetails
TrifluoperazineP-glycoprotein 1Ki (nM)6500N/AN/ADetails
TriflupromazineP-glycoprotein 1Ki (nM)15700N/AN/ADetails
VerapamilP-glycoprotein 1Ki (nM)1600N/AN/ADetails
VerapamilP-glycoprotein 1IC 50 (nM)2090N/AN/ADetails
VerapamilP-glycoprotein 1IC 50 (nM)1480N/AN/ADetails
VerapamilP-glycoprotein 1Ki (nM)300N/AN/ADetails
VerapamilP-glycoprotein 1IC 50 (nM)2110N/AN/ADetails
VerapamilP-glycoprotein 1Ki (nM)2500N/AN/ADetails
VerapamilP-glycoprotein 1IC 50 (nM)2370N/AN/ADetails
VinblastineP-glycoprotein 1Ki (nM)100N/AN/ADetails
VinblastineP-glycoprotein 1IC 50 (nM)34000N/AN/ADetails
VinblastineP-glycoprotein 1Ki (nM)1300N/AN/ADetails